146764-26-3
146764-26-3
Chemical Structure
D-20133
- CAS No.: 146764-26-3
- Formula:C26H54NO4P
- Molecular Weight:475.69
IUPAC Name: 2-(1-methylpiperidin-1-ium-1-yl)ethyl octadecyl phosphate
InChIKey: CUQJLYFFQBHUGW-UHFFFAOYSA-N
SMILES: CCCCCCCCCCCCCCCCCCOP(OCC[N+]1(CCCCC1)C)([O-])=O
Biological Activity: D-20133 is an orally active Hexadecylphosphocholine analog. D-20133 can both enhance and inhibit antigen-induced histamine release. D-20133 shows antineoplastic activity against small DMBA (HY-W011845)-induced mammary carcinomas[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
D-20133 | D-20133 is an orally active Hexadecylphosphocholine analog. D-20133 can both enhance and inhibit antigen-induced histamine release. D-20133 shows antineoplastic activity against small DMBA (HY-W011845)-induced mammary carcinomas. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Grosman N. Effect of the anti-neoplastic agents edelfosine (ET-18-OCH3), ilmofosine (BM 41.440) and the hexadecylphosphocholine analogues D-20133 and D-21266 on histamine release from isolated rat mast cells. Immunopharmacology. 1999 Nov;44(3):211-21. [Content Brief]
- [2]. Stekar J, et al. Antineoplastic activity and tolerability of a novel heterocyclic alkylphospholipid, D-20133. Cancer Chemother Pharmacol. 1993;32(6):437-44. [Content Brief]
